Trial Profile
A Phase II, double blind, randomised, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms PAKT
- 22 Jul 2020 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.
- 24 Feb 2020 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2020.